These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6661730)

  • 1. Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer's dementia: a neuropsychological and computerized electroencephalographic study.
    Agnoli A; Martucci N; Manna V; Conti L; Fioravanti M
    Clin Neuropharmacol; 1983; 6(4):311-23. PubMed ID: 6661730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of cholinergic drug effects on memory in Alzheimer's disease.
    Brinkman SD; Gershon S
    Neurobiol Aging; 1983; 4(2):139-45. PubMed ID: 6355883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinergic drugs, affective disorders and dementia: problems of clinical research.
    Spiegel R
    Acta Psychiatr Scand Suppl; 1991; 366():66-9. PubMed ID: 1897378
    [No Abstract]   [Full Text] [Related]  

  • 4. Can drugs improve memory?
    Kent S
    Geriatrics; 1979 Jul; 34(7):77, 80, 83 passim. PubMed ID: 376407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?
    Gainotti G; Nocentini U; Sena E
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13 Suppl():S47-59. PubMed ID: 2694229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scopolamine challenges in Alzheimer's disease.
    Sunderland T; Tariot P; Murphy DL; Weingartner H; Mueller EA; Cohen RM
    Psychopharmacology (Berl); 1985; 87(2):247-9. PubMed ID: 3931154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple memory deficits in Alzheimer-type dementia: implications for pharmacotherapy.
    Kopelman MD
    Psychol Med; 1985 Aug; 15(3):527-41. PubMed ID: 4048315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT).
    Wettstein A; Spiegel R
    Psychopharmacology (Berl); 1984; 84(4):572-3. PubMed ID: 6441959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.
    Perry EK; Tomlinson BE; Blessed G; Bergmann K; Gibson PH; Perry RH
    Br Med J; 1978 Nov; 2(6150):1457-9. PubMed ID: 719462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Alzheimer's disease with cholinergic drugs.
    Kumar V; Calache M
    Int J Clin Pharmacol Ther Toxicol; 1991 Jan; 29(1):23-37. PubMed ID: 2004862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of physostigmine on constructional and memory tasks in Alzheimer's disease.
    Muramoto O; Sugishita M; Sugita H; Toyokura Y
    Arch Neurol; 1979 Aug; 36(8):501-3. PubMed ID: 508162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bethanechol decreases reaction time in senile dementia of the Alzheimer type.
    Davous P; Lamour Y
    J Neurol Neurosurg Psychiatry; 1985 Dec; 48(12):1297-9. PubMed ID: 4087006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memory and attention in patients with senile dementia of the Alzheimer type and in normal elderly subjects.
    Lines CR; Dawson C; Preston GC; Reich S; Foster C; Traub M
    J Clin Exp Neuropsychol; 1991 Sep; 13(5):691-702. PubMed ID: 1955525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations.
    Sunderland T; Tariot PN; Newhouse PA
    Brain Res; 1988 Dec; 472(4):371-89. PubMed ID: 3066441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scopolamine model of dementia: electroencephalogram findings and cognitive performance.
    Ebert U; Kirch W
    Eur J Clin Invest; 1998 Nov; 28(11):944-9. PubMed ID: 9824440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.
    Sunderland T; Tariot PN; Cohen RM; Weingartner H; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1987 May; 44(5):418-26. PubMed ID: 3579494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic modelling of Alzheimer's disease.
    Sunderland T; Tariot PN; Weingartner H; Murphy DL; Newhouse PA; Mueller EA; Cohen RM
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):599-610. PubMed ID: 3541054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cholinergic enhancement therapies on memory function in Alzheimer's disease: a meta-analysis of the literature.
    Jorm AF
    Aust N Z J Psychiatry; 1986 Jun; 20(2):237-40. PubMed ID: 3464268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 12th J. A. F. Stevenson memorial lecture. Aging, Alzheimer's disease, and the cholinergic system.
    McGeer PL
    Can J Physiol Pharmacol; 1984 Jul; 62(7):741-54. PubMed ID: 6149804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.